In today’s session Inogen Inc (INGN) recorded an unusually high (335) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the December, 2016 put, expecting serious INGN decrease. With 335 contracts traded and 564 open interest for the Dec, 16 contract, it seems this is a quite bearish bet. The option with symbol: INGN161216P00060000 closed last at: $4.6 or 8% down. About 28,438 shares traded hands. Inogen Inc (NASDAQ:INGN) has risen 27.57% since April 7, 2016 and is uptrending. It has outperformed by 22.79% the S&P500.
Inogen Inc (NASDAQ:INGN) Ratings Coverage
Out of 4 analysts covering Inogen (NASDAQ:INGN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $68.0 is the highest target while $48 is the lowest. The $58.25 average target is 0.62% above today’s ($57.89) stock price. Inogen has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Wednesday, August 12 by Stifel Nicolaus. The rating was maintained by Leerink Swann with “Buy” on Wednesday, August 12. The stock has “Strong Buy” rating given by Needham on Wednesday, November 11. The company was maintained on Tuesday, September 22 by Stifel Nicolaus. As per Wednesday, July 13, the company rating was initiated by JP Morgan. The rating was initiated by Piper Jaffray with “Neutral” on Thursday, March 24.
According to Zacks Investment Research, “Inogen, Inc. is a medical technology company. It offers oxygen concentrator, cart, carry bags, backpacks, external battery chargers and universal power supply for obstructive pulmonary disease patients. The Company’s products include Inogen One G3 and Inogen One G2. It sells its products in the United States and internationally. Inogen, Inc. is headquartered in Goleta, California.”
Insitutional Activity: The institutional sentiment decreased to 0.92 in Q2 2016. Its down 0.52, from 1.44 in 2016Q1. The ratio dropped, as 22 funds sold all Inogen Inc shares owned while 54 reduced positions. 18 funds bought stakes while 52 increased positions. They now own 21.40 million shares or 1.51% more from 21.09 million shares in 2016Q1.
Lord Abbett Communications Lc last reported 322,287 shares in the company. Jpmorgan Chase reported 427,775 shares or 0.01% of all its holdings. Geode Mgmt Limited Com has invested 0% of its portfolio in Inogen Inc (NASDAQ:INGN). Blackrock Fund Advisors, a California-based fund reported 1.06M shares. The United Kingdom-based Gsa Capital Prtnrs Llp has invested 0.07% in Inogen Inc (NASDAQ:INGN). Barclays Public Limited Co holds 0% of its portfolio in Inogen Inc (NASDAQ:INGN) for 50,700 shares. Polar Llp holds 0.18% of its portfolio in Inogen Inc (NASDAQ:INGN) for 193,524 shares. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Inogen Inc (NASDAQ:INGN). Sei Invs Communication holds 7,923 shares or 0% of its portfolio. Moreover, Ogorek Anthony Joseph Ny Adv has 0% invested in Inogen Inc (NASDAQ:INGN) for 100 shares. Novo A S holds 18.67% of its portfolio in Inogen Inc (NASDAQ:INGN) for 3.55M shares. Kalmar Invs De accumulated 434,845 shares or 0.96% of the stock. Goldman Sachs Grp Inc holds 13,445 shares or 0% of its portfolio. The New York-based New York State Teachers Retirement System has invested 0% in Inogen Inc (NASDAQ:INGN). California Employees Retirement System last reported 0% of its portfolio in the stock.
Inogen, Inc. is a medical technology company. The company has a market cap of $1.17 billion. The Firm is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It has a 81.64 P/E ratio. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
INGN Company Profile
Inogen, Inc., incorporated on November 27, 2001, is a medical technology company. The Firm is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.